Procédé de fabrication d'une forme pharmaceutique à libération contrôlée contenant au moins un principe actif
| hal.structure.identifier | Ellipse Pharmaceutical | |
| dc.contributor.author | LACAZE SAINT-JEAN, Catherine | |
| hal.structure.identifier | Ellipse Pharmaceutical | |
| dc.contributor.author | GRISLAIN, Luc | |
| hal.structure.identifier | Ellipse Pharmaceutical | |
| dc.contributor.author | BERGUA, Thomas | |
| hal.structure.identifier | Ellipse Pharmaceutical | |
| dc.contributor.author | BOUTIGNON, François | |
| hal.structure.identifier | Institut de Chimie de la Matière Condensée de Bordeaux [ICMCB] | |
| dc.contributor.author | DEMAZEAU, Gérard | |
| hal.structure.identifier | Institut de Chimie de la Matière Condensée de Bordeaux [ICMCB] | |
| dc.contributor.author | LARGETEAU, Alain | |
| dc.date.issued | 2006-01-06 | |
| dc.description.abstractEn | A manufg. process for an administrable or implantable controlled-release dosage form contg. at least an active ingredient comprises mixing the active ingredients with a vector comprising one or more excipients and subjecting the mixt. to a treatment by high isostatic pressure ranging from 100-700 MPa for a length of time ranging between 1 and 60 min, to form the pharmaceutical form. Pharmaceutical forms obtained by this process are implanted or administered by oral, nasal, parenteral, vaginal, rectal or ophthalmic route. A tablet contg. ibuprofen 60, lactose 35, talc 4, colloidal silica 0.5, and magnesium stearate 0.5% was prepd. according to the above process. | |
| dc.language.iso | fr | |
| dc.subject.en | Drug delivery system | |
| dc.subject.en | Pressure | |
| dc.subject.en | Vinyl compounds | |
| dc.subject.en | Acrylic polymers | |
| dc.subject.en | Insulin | |
| dc.subject.en | Ibuprofen | |
| dc.subject.en | Resomer rg 502h | |
| dc.subject.en | Biological studies | |
| dc.title | Procédé de fabrication d'une forme pharmaceutique à libération contrôlée contenant au moins un principe actif | |
| dc.type | Brevet | |
| dc.subject.hal | Chimie/Matériaux | |
| bordeaux.page | 22 | |
| bordeaux.country | FR | |
| bordeaux.brevet.number | FR 2872429 | |
| hal.identifier | hal-00018632 | |
| hal.version | 1 | |
| hal.origin.link | https://hal.archives-ouvertes.fr//hal-00018632v1 | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.title=Proc%C3%A9d%C3%A9%20de%20fabrication%20d'une%20forme%20pharmaceutique%20%C3%A0%20lib%C3%A9ration%20contr%C3%B4l%C3%A9e%20contenant%20au%20moins%20un%20principe%20actif&rft.atitle=Proc%C3%A9d%C3%A9%20de%20fabrication%20d'une%20forme%20pharmaceutique%20%C3%A0%20lib%C3%A9ration%20contr%C3%B4l%C3%A9e%20contenant%20au%20moins%20un%20principe%20actif&rft.date=2006-01-06&rft.spage=22&rft.epage=22&rft.au=LACAZE%20SAINT-JEAN,%20Catherine&GRISLAIN,%20Luc&BERGUA,%20Thomas&BOUTIGNON,%20Fran%C3%A7ois&DEMAZEAU,%20G%C3%A9rard&rft.genre=unknown |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||